company background image
NTI

Neurotech InternationalASX:NTI Stock Report

Market Cap

AU$36.2m

7D

12.2%

1Y

120.0%

Updated

26 Oct, 2021

Data

Company Financials
NTI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NTI Overview

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Neurotech International
Historical stock prices
Current Share PriceAU$0.055
52 Week HighAU$0.021
52 Week LowAU$0.084
Beta2.62
1 Month Change25.00%
3 Month Change5.77%
1 Year Change120.00%
3 Year Change-31.25%
5 Year Changen/a
Change since IPO-80.70%

Recent News & Updates

Sep 04
Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Neurotech...

Shareholder Returns

NTIAU Medical EquipmentAU Market
7D12.2%0.3%0.8%
1Y120.0%-7.4%24.4%

Return vs Industry: NTI exceeded the Australian Medical Equipment industry which returned -7.4% over the past year.

Return vs Market: NTI exceeded the Australian Market which returned 24.4% over the past year.

Price Volatility

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Beta2.62
Industry Beta0.57
Market Beta1

Stable Share Price: NTI is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: NTI's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016n/aPeter James Griffithshttps://www.neurotechinternational.com

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on developing neurostimulation and neurodiagnostic solutions to be delivered through the Mente platform, a platform technology to enable medical practitioners to remotely monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism.

Neurotech International Fundamentals Summary

How do Neurotech International's earnings and revenue compare to its market cap?
NTI fundamental statistics
Market CapAU$36.23m
Earnings (TTM)-AU$7.43m
Revenue (TTM)AU$225.54k

171.9x

P/S Ratio

-5.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NTI income statement (TTM)
RevenueAU$225.54k
Cost of Revenue-AU$20.34k
Gross ProfitAU$245.88k
ExpensesAU$7.68m
Earnings-AU$7.43m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.011
Gross Margin109.02%
Net Profit Margin-3,294.65%
Debt/Equity Ratio0.0%

How did NTI perform over the long term?

See historical performance and comparison

Valuation

Is Neurotech International undervalued compared to its fair value and its price relative to the market?

9.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NTI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NTI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NTI is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: NTI is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NTI is overvalued based on its PB Ratio (9.9x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Neurotech International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neurotech International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Neurotech International performed over the past 5 years?

-6.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NTI is currently unprofitable.

Growing Profit Margin: NTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NTI is unprofitable, and losses have increased over the past 5 years at a rate of 6.5% per year.

Accelerating Growth: Unable to compare NTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: NTI has a negative Return on Equity (-192.43%), as it is currently unprofitable.


Financial Health

How is Neurotech International's financial position?


Financial Position Analysis

Short Term Liabilities: NTI's short term assets (A$5.0M) exceed its short term liabilities (A$349.4K).

Long Term Liabilities: NTI's short term assets (A$5.0M) exceed its long term liabilities (A$795.0K).


Debt to Equity History and Analysis

Debt Level: NTI is debt free.

Reducing Debt: NTI has no debt compared to 5 years ago when its debt to equity ratio was 61.8%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NTI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NTI has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 17.5% each year.


Dividend

What is Neurotech International current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NTI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Peter James Griffiths (57 yo)

1

Tenure

AU$109,031

Compensation

Mr. Peter James Lawrence Griffiths, B.Sc. (Hons), has been the Chief Executive Officer of AAT Research Ltd at Neurotech International Limited since October 2020 and served as its Chief Executive Officer an...


CEO Compensation Analysis

Compensation vs Market: Peter James's total compensation ($USD81.73K) is below average for companies of similar size in the Australian market ($USD301.38K).

Compensation vs Earnings: Peter James's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NTI's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: NTI's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 79.3%.


Top Shareholders

Company Information

Neurotech International Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Neurotech International Limited
  • Ticker: NTI
  • Exchange: ASX
  • Founded: 2016
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$36.235m
  • Shares outstanding: 696.82m
  • Website: https://www.neurotechinternational.com

Location

  • Neurotech International Limited
  • 145 Stirling Highway
  • Suite 5 CPC
  • Nedlands
  • Western Australia
  • 6009
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 07:02
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.